Neo Fusion

1.1 Identity, location, and operating model

Neo Fusion, also identified in Chinese records as 聚变新能（安徽）有限公司, was founded in 2023 and is located in Hefei, Anhui, China. FusionXInvest describes the company as developing controlled-fusion technologies for global commercial use, with a primary focus on designing and developing a tokamak fusion device. Its company profile says Neo Fusion is majority owned by state-owned enterprises, including China National Petroleum Corporation and Hefei Science Island, which is controlled by the Chinese Academy of Sciences. The Baidu Baike record describes the company as a research-and-engineering vehicle whose operating scope includes emerging-energy research, nuclear-power equipment engineering services, power-generation technical services, and related engineering and intellectual-property services. This evidence supports a pre-commercial, state-linked technology-development model rather than a demonstrated merchant-power business. No source in the assigned pool establishes paying customers, commercial revenue, ARR, or a completed power-plant project.[CO001, CO002, CO003, CO004]

1.2 Ownership, capital, and governance visibility

The available evidence indicates a government-linked capitalization structure, but it does not show the distinction between registered capital, paid-in capital, committed project funding, and cash available for construction. Baidu Baike records an initial registered capital of RMB5 billion at formation and RMB14.5 billion after a 2024 increase, and identifies China National Petroleum Group Kunlun Capital and Hefei Science Island Holdings as shareholders added that year. These figures should not be treated as a valuation or as cash runway. The same record names Huang Suzhen as legal representative from December 2024, but the public pool does not provide a cap table, investor-rights schedule, debt terms, board composition, founder biographies, or a complete executive roster. That opacity is material because the project is capital-intensive and the ownership structure may determine control, funding continuity, and access for outside capital.[CO003, CO005, CO006, CO007, CO008, CO015]

1.3 Milestones and commercialization readiness

Neo Fusion's observable milestone path is centered on BEST, a compact tokamak fusion experiment intended to bridge research capability and a future commercial route. The Baidu Baike record says the company was formed on 2023-05-19, describes the 2024 ownership and registered-capital change, reports that BEST engineering assembly began in 2025, and records a 2026-09-27 shipment of batch-manufactured TF coil boxes. It also states a plan for assembly completion in 2027 and fusion-energy output greater than input in 2030; those are plans or reported targets, not achieved operating results. Independent comparator evidence shows why engineering execution matters: MIT reports a 20-tesla high-temperature-superconducting magnet test for a different fusion program, while TechCrunch reports that Commonwealth Fusion Systems was still commissioning a first-of-kind tokamak after installing a cryostat base. These comparisons provide context for execution risk, not evidence that Neo Fusion has matched those milestones. A sector research source separately identifies high capital cost, technical complexity, regulatory uncertainty, and slow permitting as commercialization constraints. The assigned pool contains no source that verifies Neo Fusion revenue, customers, valuation, headcount, safety case, or regulatory approval.[CO009, CO010, CO011, CO012, CO013, CO014, CO016]

1.4 Exhibits

2.1 Market boundary and status quo

The relevant market for Neo Fusion is the development and deployment of controlled fusion systems, with BEST positioned as an intermediate experimental tokamak between EAST and the future CFEDR. That boundary includes public research programs, private reactor developers, superconducting magnets, plasma-control and diagnostics, cryogenic and materials systems, and eventual power-plant engineering. It excludes today's general electricity market, unsupported claims of current fusion power sales, and unrelated nuclear-fission generation. The evidence describes fusion as a prospective source of low-carbon baseload power, with adjacent applications in industrial heat, hydrogen production, and space propulsion, but those are downstream options rather than demonstrated Neo Fusion revenue pools. The status quo is therefore a mix of conventional generation, renewables, fission, and continued experimental research; a fusion buyer must justify reliability, cost, safety, and schedule against those alternatives.[CM001, CM002, CM003, CM004]

2.2 Sizing lenses and commercialization timing

Published market estimates show why a single TAM number would be misleading. Precedence Research estimates a global nuclear-fusion market of USD 471.99 billion in 2030 and USD 843.46 billion in 2040, while Maximize Market Research reports USD 347.48 billion in 2025 and USD 572.74 billion in 2032. These estimates use different labels, forecast windows, and methodologies, and neither isolates Neo Fusion's serviceable segment or cashable share. The constrained near-term SAM is better represented by experimental and pilot-plant procurement, engineering supply chains, and public-private demonstration budgets. BEST's stated 2027 completion target supports a development-stage timing lens, not a forecast of commercial electricity sales. Public market reports identify power generation as the dominant application while also naming industrial heat, hydrogen, and space propulsion as emerging adjacencies; the adoption path remains contingent on machine performance, permitting, and project economics.[CM005, CM006, CM007, CM008, CM009]

2.3 Buyers, drivers, and constraints

The buyer map is staged rather than a conventional software funnel. Public science institutions and state-backed energy or research bodies are the apparent current budget owners for experimental devices and enabling infrastructure. Industrial partners, utilities, and large electricity users become prospective demonstration or offtake counterparties only after a machine clears technical and regulatory milestones. Maximize identifies clean-energy demand, public-private investment, AI-assisted plasma work, and superconducting materials as growth drivers; it also identifies high capital costs, extreme operating conditions, complex diagnostics, regulatory uncertainty, safety concerns, and slow permitting as constraints. The MIT account of CFS's magnet program shows that advanced magnets can improve the engineering case, but its described commissioning and failure testing also illustrate that first-of-a-kind systems require specialized supply chains, validation, and schedule tolerance. For Neo Fusion, the key valuation question is whether BEST converts state-supported development capability into reproducible reactor, licensing, and eventual offtake economics.[CM010, CM011, CM012, CM013, CM014]

2.4 Evidence limits and diligence implications

The assigned evidence does not establish a Neo Fusion-specific SAM, SOM, tariff, host site, customer, purchase agreement, or unit-economics model. It also does not show how registration-capital figures translate into deployable project cash, nor whether BEST's 2027 completion target means first plasma, integrated commissioning, or another milestone. The market reports are useful directional lenses but are not substitutes for a bottom-up bill of materials, schedule, permitting plan, or power-market model. Accordingly, market attractiveness is credible at the sector level but commercialization confidence remains low-to-medium. Investors should request a milestone-linked budget, machine performance thresholds, a regulatory and tritium/waste package, named counterparties or offtake evidence, and a geography-specific comparison with fission, renewables, storage, and grid procurement alternatives before underwriting a large serviceable market.[CM015, CM016]

2.5 Exhibits

3.1 Landscape and strategic position

Neo Fusion competes in a heterogeneous field rather than a single product market. Its disclosed path is a tokamak and BEST-centered engineering program, with company-profile evidence describing a 2023 founding and a majority state-owned structure. The Chinese program context is material: Xinhua reported that BEST is intended to demonstrate net fusion power gain and electricity generation around 2030, while also placing the project in a broader national move from fundamental research toward engineering. The nearest direct commercial comparison in the retained evidence is Commonwealth Fusion Systems (CFS), whose SPARC tokamak is being assembled for a planned 2027 start and whose ARC plant has a stated Virginia site. Other alternatives include laser-based inertial confinement at the National Ignition Facility, established public programs such as ITER, and other private concepts such as Helion, TAE, General Fusion, and Tokamak Energy. These are not interchangeable products: they differ in plasma configuration, maturity, financing model, and intended route to grid power.[CP002, CP003, CP004]

3.2 Buyer trade-offs, capability, and distribution

A future fusion buyer is likely to value credible net-power performance, repeatable component manufacturing, regulatory readiness, schedule confidence, and a path to plant financing more than a laboratory milestone alone. CFS provides a useful comparator because TechCrunch describes both a physical SPARC assembly milestone and a multi-month commissioning process, while MIT's account of the underlying REBCO magnet work shows that the technology advantage depends on difficult engineering and supply-chain execution. Neo Fusion's differentiator is access to Chinese state-linked institutions and a domestic engineering ecosystem, but public sources do not disclose a commercial customer, power-purchase agreement, list price, or realized unit economics. Accordingly, the matrix separates observed capability or strategic access from unsupported commercial assumptions. Internal build and status quo remain credible categories because a buyer may defer adoption or rely on public research infrastructure rather than buy a private reactor, but this pool does not support a quantified comparison of those alternatives.[CP005, CP006, CP007, CP008]

3.3 Moat durability and displacement risk

Neo Fusion's potential moat is institutional and execution-based rather than a proven recurring software-style lock-in. The disclosed combination of Chinese Academy of Sciences-linked research, state-owned capital, and BEST engineering access may improve patient capital, procurement, and domestic coordination. It does not by itself establish superior reactor economics. CFS has demonstrated a different form of advantage through high-temperature-superconductor magnet development, private-company construction, and a stated commercial-site plan; MIT reports that the magnet program included full-scale testing and supply-chain procurement. The competitive threat is therefore milestone convergence: if several concepts reach net power, the advantage may move to manufacturing yield, licensing, financing, grid integration, and delivered cost. The retained evidence does not establish Neo Fusion's pricing, export strategy, component exclusivity, or customer switching costs, so those items remain diligence gaps rather than asserted weaknesses. Sector research also identifies high capital cost, plasma-stability complexity, and regulatory uncertainty as common constraints, so schedule slippage or cost escalation can erode differentiation without a superior reactor concept emerging.[CP009, CP010, CP011, CP012, CP015, CP016]

3.4 Evidence boundary and open issues

The comparison is deliberately evidence-constrained. Public market reports list many fusion concepts and describe intense competition, but their market-size forecasts are not direct evidence of Neo Fusion's obtainable market or of any competitor's realized economics. Unknown cells should be treated as underwriting gaps, not as evidence that a competitor lacks the capability. The table therefore distinguishes technical pathway, observed construction, and commercial evidence, since those dimensions mature on different schedules and cannot be collapsed into one unverified ranking.[CP013, CP014]

3.5 Exhibits

4.1 Revenue model and monetization visibility

Neo Fusion's public profile describes a 2023-founded Anhui company focused on controlled-fusion technology and tokamak development, not a commercial product with disclosed customers or contract terms. Its public-facing activity is framed around building a fusion device and participating in an emerging industrial ecosystem. That supports an R&D or project-development interpretation, but it does not establish recurring revenue, recognized revenue, ARR, GMV, utilization, or realized pricing. The financial underwriting consequence is that any future monetization is contingent on technical milestones, project finance, and eventual power or technology commercialization rather than current operating cash generation. Official or customer contracts, revenue recognition policies, backlog, and paid pilot evidence remain unavailable in the assigned evidence.[CI001, CI002, CI003, CI004]

4.2 Cost structure and unit economics

Fusion development has a structurally heavy cost base: high-temperature plasma systems, superconducting magnets, cryogenics, vacuum systems, diagnostics, specialized fabrication, site infrastructure, and engineering labor must be funded before commercial output. Comparable public reporting describes SPARC assembly around a 1,000-tonne machine, major cryostat and magnet interfaces, and a planned commercial plant, illustrating why a prototype-to-power pathway should not be modeled like a software business. Market research also identifies high capital costs and technological complexity as commercialization constraints. Neo Fusion-specific gross margin, engineering cost per milestone, manufacturing yield, service-delivery cost, working-capital cycle, and capex schedule are not publicly established.[CI005, CI006, CI007, CI008]

4.3 Capital adequacy and financing dependency

The available evidence points to financing dependency without providing a cash balance or runway. A company profile says Neo Fusion is majority owned by state-owned enterprises including China National Petroleum Corporation and Hefei Science Island, and Baidu Baike reports that registered capital increased from RMB 5.0 billion to RMB 14.5 billion in 2024. Registered capital is not evidence of paid-in capital or cash available for operations. A 2026 Anhui report separately describes planned university collaboration and a broader fusion-industry ecosystem. These facts may indicate institutional sponsorship and access to an industrial network, but they do not establish unrestricted cash, debt terms, committed project finance, or investor rights. The assigned FusionXInvest headline flags a possible reduction in investor exposure, but the fetched page exposes only a membership gate; neither the transaction nor its rationale is verified. The appropriate conclusion is financing uncertainty, not a precise solvency judgment.[CI009, CI010, CI011, CI012, CI016]

4.4 Financial verdict and diligence blockers

Neo Fusion's financial profile is best treated as pre-commercial infrastructure and technology underwriting. Industry sources describe growing private fusion investment and future power-purchase activity, but those are sector comparables and not Neo Fusion revenue, valuation, or cash availability. A market report forecasts large fusion-market totals while simultaneously describing high capital costs, technical complexity, regulatory uncertainty, and possible delays beyond 2030; those forecasts are directional context, not a company forecast. The central diligence question is whether a verified financing plan bridges the company from current engineering work to first plasma, then to a power-generating demonstration and customer or offtake contracts. Until management supplies audited financials, cap table, cash and burn schedule, milestone budget, debt/project-finance obligations, and commercialization terms, the recommendation should remain research-more with low confidence in financial underwriting.[CI013, CI014, CI015]

5.1 Product definition and maturity

Neo Fusion's product is not a commercial electricity tariff or an operating power plant; it is the BEST experimental fusion platform and the engineering capability around it. A company profile describes Neo Fusion as founded in 2023 in Anhui and focused on designing and developing a tokamak fusion device. The company profile also describes majority ownership by state-owned enterprises including China National Petroleum Corporation and Hefei Science Island, controlled by the Chinese Academy of Sciences. A separate company-information page says the business was established on 19 May 2023 and describes BEST as its main project, but that page is a secondary directory rather than an audited technical disclosure. Independent coverage says BEST construction began in 2023, the main building was complete, and component pre-assembly had begun; it reports expected completion in 2027. That is meaningful physical maturity, but it is not evidence that the device has achieved plasma performance, net energy, or power-plant reliability.[CE001, CE002, CE003, CE004]

5.2 Architecture and operating workflow

The disclosed architecture is a compact, high-field tokamak with superconducting magnets, long-pulse operation, and a burning-plasma research objective. The Institute of Plasma Physics at the Max Planck Society describes the comparison stellarator Wendelstein 7-X as using 50 non-planar superconducting coils to produce its optimized magnetic field and to investigate continuous operation; this is a useful external benchmark for the engineering burden of superconducting magnetic confinement, not a claim about Neo Fusion's design. The BEST descriptions instead emphasize high neutron fluence, high density, and high energy and particle flux as deliberate test conditions. CAS reporting says the planned experiments use deuterium-tritium burning plasma, target 20 to 200 megawatts of fusion power, and seek net energy gain. The workflow therefore runs from superconducting magnetic confinement and plasma heating through long-pulse burning-plasma experiments and measurement of energy and particle exhaust; public material does not disclose a complete subsystem bill of materials, tritium-breeding design, heat-extraction design, or control-system performance.[CE005, CE006, CE007, CE008, CE009]

5.3 Differentiation, dependencies, and technical risks

Neo Fusion's potential differentiation is the combination of a compact high-field burning-plasma device, access to Hefei's research ecosystem, and a stated bridge from EAST to a future CFEDR-class demonstration path. CAS says the international program opens major Hefei fusion platforms to scientists from more than ten countries, while the DOE's June 2026 roadmap frames commercial fusion around unresolved science, materials, and technology gaps and a fusion pilot-plant path in the 2030s. Those external references reinforce that BEST is strategically relevant, but they do not validate Neo Fusion's own performance. A Chinese information page reports a plan to complete BEST assembly in 2027 and achieve fusion energy output greater than input in 2030; this is a company/project roadmap claim, not an observed result. The principal diligence risks are therefore unverified first-plasma and net-energy milestones, high-flux materials and component lifetime, tritium and waste handling, thermal and electrical integration, control reliability, and the absence of a public machine-level safety or regulatory package. A sector market report also notes that continuous commercial-scale fusion is difficult because plasma stability requires sophisticated control and small technical failures can cause costly delays; its forecasts are not Neo Fusion-specific evidence.[CE010, CE011, CE012, CE013, CE014, CE015, CE016]

5.4 Exhibits

6.1 Buyer, user, and ecosystem roles

Neo Fusion's evidenced counterparties are capital and institutional stakeholders rather than disclosed commercial customers. Reuters reported that Anhui government-owned energy companies and investment arms controlled 50% of the company at formation, while Nio and Nio Capital held 19.9% and 10.1% respectively. CnEVPost described the project as intended to attract additional strategic and financial investors in phases, and FusionXInvest describes a primary focus on designing and developing a tokamak device. This points to a stakeholder model in which state-linked energy entities may be future hosts, infrastructure partners, or offtake enablers, while Nio is a strategic investor and potential industrial ecosystem participant; none of those roles, by themselves, proves a paying customer relationship. The available record does not identify a signed power purchaser, a utility offtake contract, a paid pilot, or a recurring commercial service.[CU001, CU002, CU003, CU004]

6.2 Adoption and named proof

The observable trajectory is project formation and technical development, not market adoption. Public descriptions place the company in Hefei and characterize its activity as controlled-fusion research and tokamak development; the referenced company profile does not report customer counts, production sites, utilization, revenue, or renewals. The customer-facing proof available in this pool is indirect: Nio's investment and the surrounding Anhui energy infrastructure context demonstrate strategic interest, while the public energy plan describes system-level demand for generation, transmission, storage, and flexibility. Those signals can support a future partner-development hypothesis, but they cannot be converted into active-account or deployment metrics. A diligence-ready adoption series therefore has missing denominators and missing commercial milestones. A September 2026 BEST component shipment is evidence of construction progress, not customer acceptance. By comparison, a fusion peer has publicly documented external-supplier coordination, illustrating the kind of third-party execution trail Neo Fusion has not disclosed in this assigned evidence; the competitor example is not an independent benchmark or proof of equivalent maturity.[CU005, CU006, CU007, CU008, CU015, CU016]

6.3 Durability, expansion, and concentration

No source in the assigned pool reports Neo Fusion's NRR, GRR, churn, renewal rate, contract length, customer satisfaction, or revenue concentration. The clearest concentration signal is ownership and ecosystem dependence: Reuters attributes half of the initial control to Anhui government-owned energy companies and investment arms, while Nio and Nio Capital together represented 30% of the disclosed equity stakes. That structure may provide patient strategic support, but it also leaves outside investors without evidence that demand is diversified beyond state-linked capital and strategic sponsors. The Fusion Report explicitly excludes Chinese fusion-company funding from its industry totals because that market is opaque; this is an industry-level caution, not evidence of Neo Fusion customer performance. Expansion into power production would additionally require offtake, licensing, grid interconnection, and plant-economics evidence that is not disclosed here. ITER describes fusion's baseload potential but says average electricity cost cannot yet be extrapolated before operating experience and identifies reliable tritium breeding and recovery as a critical challenge. These sector-level constraints reinforce that bankable economics and fuel-cycle validation precede durable utility demand.[CU009, CU010, CU011, CU012, CU013, CU014]

7.1 Regulatory and legal exposure

Nuclear regulation is a gating risk rather than a routine compliance item for a pre-commercial fusion developer. China's Nuclear Safety Law applies to nuclear facilities, nuclear materials, and radioactive waste, and requires licensing for siting, construction, operation, and decommissioning. It also assigns the operator overall nuclear-safety responsibility and requires safety analysis, environmental-impact documentation, quality assurance, emergency planning, and financial protection. The retained record does not show a Neo Fusion-specific license, safety analysis, environmental approval, or regulator decision. Until those documents are produced, the probability and timing of regulatory delay remain unresolved, and the investment case should treat first plasma and any later power-production milestone as conditional rather than scheduled.[CR001, CR002, CR003, CR004]

7.2 Operational, technical, and commercialization risk

The central operating risk is not merely whether a fusion pulse can be produced, but whether a repeatable, maintainable and licensable plant can be built at an economic cost. A Baidu-compiled profile reports that BEST assembly began in May 2025, with completion planned for 2027 and energy output above input planned for 2030; this is a milestone narrative, not an independently audited schedule or performance result. The public evidence available to this chapter does not document Neo Fusion's machine-level safety case, tritium and radioactive-waste handling, uptime, component lifetime, or independently verified energy gain. Broader energy evidence warns that levelized cost does not capture every system-level effect. The appropriate mitigation is staged technical disclosure with independent review and explicit go/no-go criteria for plasma performance, availability, safety, and cost.[CR005, CR006, CR007, CR008, CR015]

7.3 Partner, capital, and execution dependencies

Fusion commercialization is capital- and ecosystem-intensive, and the assigned evidence does not establish Neo Fusion's cash balance, paid-in capital, debt, committed financing, supplier concentration, or customer contracts. FusionXInvest reports majority ownership by state-owned entities, creating a material governance and strategic-capital dependency whose exact rights remain undisclosed. A funding announcement from another fusion company illustrates sector capital requirements but is not evidence of Neo Fusion's runway. As a commercial benchmark, Google signed a 200 MW agreement with Commonwealth Fusion Systems that POWER reports is tied to SPARC reaching net fusion energy. Diligence should obtain a cap table, paid-in-capital schedule, milestone budget, governance rights, procurement plan, and binding offtake or host-site commitments.[CR009, CR010, CR011, CR014, CR016]

7.4 Monitoring and thesis-break triggers

The practical risk framework is to monitor evidence that converts an unresolved question into a measurable failure. A thesis break would include a missed licensing gate without a documented revised path, material slippage against the reported 2027 assembly or 2030 net-energy milestones without a funded recovery plan, failure to demonstrate repeatable machine performance against a published metric, a material increase in required capital without committed sources, loss of a critical partner or supplier without replacement, or inability to show a credible safety, waste, maintenance, and grid-integration package. These triggers are evidence-based because the assigned pool contains no confirmed Neo Fusion incident, lawsuit, outage, or customer-loss record. That absence is not proof that no such event occurred.[CR003, CR004, CR006, CR010, CR015, CR016]

7.5 Exhibits

8.1 Investment case and anti-thesis

The investment case is strategic rather than conventionally financial. Public descriptions place Neo Fusion at the intersection of Hefei's fusion-science base, state-linked capital, and a commercial vehicle intended to move BEST from experiment toward later demonstration and power applications. The company was established in 2023, and the accessible company profile describes tokamak development and majority ownership by state-owned enterprises. A separate 36Kr report says registered capital rose from CNY 5 billion to CNY 14.5 billion and identifies CNY 2.9 billion from China National Petroleum Kunlun Capital for a 20% stake. Those figures are capital-structure signals, not a priced financing valuation or proof that the full registered-capital amount is paid in and available for construction. The anti-thesis is therefore material: the public record still lacks an outside-investor price, cap-table rights, cash runway, revenue, offtake, or a machine-to-grid economics bridge. The DOE roadmap is useful context, not Neo Fusion evidence: it says private fusion investment exceeds $10 billion while critical materials and fuel-cycle gaps remain.[CV001, CV002, CV003, CV004, CV005]

8.2 Financing context and market discipline

Fusion financing is attracting large strategic and institutional commitments, but sector funding should not be used as a proxy for Neo Fusion's valuation. The Fusion Report describes Commonwealth Fusion Systems' July 2026 additional $1 billion equity financing and a $4 billion cumulative total, while Helion's June 2026 round carried a reported $15.5 billion post-money valuation. These are competitor transactions with different technologies, jurisdictions, milestones, and disclosure; they are not comparable-company marks for Neo Fusion. Market research reports also publish very large addressable-market forecasts, but their definitions combine research, equipment, pilot plants, and future power applications, so they do not establish serviceable revenue or a company-level multiple. The more decision-useful external discipline is cost and deployment learning: Our World in Data reports an 88% fall in utility-scale solar electricity cost from 2009 to 2024, while Lazard's 2026 LCOE+ summary says renewables remain the most cost-competitive unsubsidized new-build generation. Fusion must ultimately clear those alternatives on delivered cost, reliability, schedule, and financing risk; no retained source demonstrates that Neo Fusion does so today.[CV006, CV007, CV008, CV009, CV010]

8.3 Scenarios, recommendation, and entry discipline

A defensible scenario framework is milestone-based, not a discounted-cash-flow exercise. The favorable case requires BEST to meet its disclosed engineering sequence, demonstrate energy output greater than input around 2030, and convert scientific capability into a funded demonstration and credible commercial pathway. The base case is continued strategic financing and technical progress without enough public evidence to underwrite a power-plant return, leaving the asset suitable for monitoring rather than a priced buy. The adverse case is schedule slippage, cost escalation, unresolved fuel-cycle or materials gaps, or a financing round that reveals dilution, preference, or governance terms unfavorable to new capital. The evidence supports research-more with low confidence in any precise valuation stance, not a buy call. Entry discipline should be defined by a verified paid-in-capital schedule, milestone budget, independent technical review, and financing terms. A numerical target return or valuation range would be false precision because current public sources do not provide Neo Fusion revenue, cash burn, project cost, ownership economics, or an exit market.[CV011, CV012, CV013, CV014]

8.4 Exit readiness and thesis-break triggers

Exit readiness is presently unproven. The retained company description identifies a three-stage ambition spanning an experimental device, an engineering demonstration device, and a commercial power station, while the Baike entry reports a 2027 assembly target and a 2030 energy-output target. Those dates are useful monitoring markers, not contracted delivery obligations or an investable exit timetable. A credible next financing or strategic exit would require evidence of technical acceptance, commercial counterparties, licensing and safety readiness, and transparent investor rights. The thesis breaks if registered capital cannot be reconciled to paid-in cash and committed uses, if BEST milestones move without a funded recovery plan, if independent engineering cannot validate performance, or if delivered-power economics are materially inferior to available low-carbon alternatives. The immediate diligence ask is a data room covering cap table, paid-in capital, preference stack, debt, budget, milestones, procurement, regulatory status, offtake, and commercialization assumptions. Until that package exists, valuation should remain unknown and recommendation research-more.[CV002, CV011, CV013, CV015]

8.5 Exhibits